



1614 ✓
CASE 4-30944A/G1

CERTIFICATE OF MAILING

I hereby certify that (this paper, along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

George R. Dohmann

Type or print name

George R. Dohmann

Signature

February 11, 2002

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FRANCE ET AL

APPLICATION NO. 10/035,301

FILED OCTOBER 25, 2001

FOR USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID
DERIVATIVES AS PROTEASOME INHIBITORS

Assistant Commissioner for Patents
Washington, D.C. 20231

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

MAR - 4 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


Some of the listed references are of record in parent Application No. 09/300,779 filed April 27, 1999, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

Also, a copy of the other cited reference is enclosed herewith.

BEST AVAILABLE COPY

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593
(908) 522-6922


Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Date: February 11, 2002

RECEIVED
MAR -4 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOC. NO.
4-30944A/C1
APPLICATION NO.
10/035,301
APPLICANT
FRANCE ET AL.
FILING DATE
OCTOBER 25, 2001

Group

COPY OF PAPERS
ORIGINALLY FILED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,538,997*	7/23/96	Billich et al.	514	510	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 93/01166	01/21/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	André P. et al., Proc. Natl. Acad. Sci. USA, Vol. 95, "An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses," pp. 13120-13124 (1998)*
	AS	Rolfe M. et al., J. Mol. Med., Vol. 75, "The ubiquitin-mediated proteolytic pathway as a therapeutic area," pp. 5-17 (1997)*
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.